An Open-label, Multi-center, Extension Study of NKTR 102 in Subjects Previously Enrolled in NKTR-102 Studies
Sponsor: Nektar Therapeutics
Location(s): United States
The study objective of this open label, multicenter study is to provide access to NKTR-102 treatment to subjects previously enrolled in a NKTR-102 study who are without signs of disease progression since receiving NKTR-102.
In addition the study will evaluate the safety of continued exposure to NKTR-102, observe disease status and survival status in subjects receiving NKTR-102, and evaluate the efficacy of NKTR-102 in subjects with advanced or metastatic solid tumors.